Latham & Watkins advised the underwriters in Adagene Inc.’s initial public offering of 7,354,000 American Depositary Shares on the Nasdaq under the symbol ADAG for a total offering size of approximately US$140 million. Goldman Sachs, Morgan Stanley and Jefferies acted as the joint bookrunners on the offering.
Adagene is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The company combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs.
The Latham team was led by Hong Kong partners Cathy Yeung, Benjamin Su, Daying Zhang, and San Diego partner Michael Sullivan, with associates Chimmy Tao and Jeffrey Woodley. Advice on tax matters was provided by partner Samuel Weiner in Los Angeles and associate Janet Hsu in Orange County; on FDA regulatory matters by partner Elizabeth Richards and associate Barrett Tenbarge in Washington D.C.; on IP matters by partner Chris Hazuka and associate Robert Yeh in San Diego.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
